Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients
Status:
RECRUITING
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients . The study was conducted in accordance with the Good Practice for Quality Control of Clinical Trials for Pharmaceutical Products (GCP). Approximately 20 subjects will be enrolled to evaluate the efficacy and safety of RC48 (2.0 mg/kg intravenously every 3 weeks) combined with Tislelizumab (200mg intravenously every 3 weeks).
Phase:
PHASE2
Details
Lead Sponsor:
RenJi Hospital
Collaborators:
Peking University First Hospital Tianjin Medical University Second Hospital West China Hospital